Choosing immunomodulating therapies for the treatment of COVID-19: recommendations based on placebo-controlled trial evidence
Open Access
- 4 January 2024
- journal article
- review article
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 30 (5) , 611-618
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19New England Journal of Medicine, 2021
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19New England Journal of Medicine, 2021
- Remdesivir for the Treatment of Covid-19 — Final ReportNew England Journal of Medicine, 2020
- Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19JAMA, 2020
- Is a “Cytokine Storm” Relevant to COVID-19?JAMA Internal Medicine, 2020
- Interleukin‐6 in Covid‐19: A systematic review and meta‐analysisReviews in Medical Virology, 2020
- Practical Guide to Meta-analysisJAMA Surgery, 2020
- Time to abandon placebo control in pivotal phase III trials?World Psychiatry, 2015
- Early Corticosteroids in Severe Influenza A/H1N1 Pneumonia and Acute Respiratory Distress SyndromeAmerican Journal of Respiratory and Critical Care Medicine, 2011
- A Controlled Trial of Early Adjunctive Treatment with Corticosteroids forPneumocystis cariniiPneumonia in the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1990